ABL1 (phospho-Y412) polyclonal antibody

Product Specifications

Background

The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV) . The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this translocation is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase. The Bcr gene has been shown to encode a GTPase-activating protein (GAP) specific for the Ras-related GTP-binding protein, p21rac.

CAS Number

9007-83-4

Structure Composition

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Product Name Alternative

Tyrosine-protein kinase ABL1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150; ABL1; ABL; JTK7

Swiss Prot

P00519

Reactivity

Human, Mouse, Rat

Immunogen

Synthetic phosphopeptide derived from human ABL1 around the phosphorylation site of Tyrosine 412.

Conjugation

Unconjugated

Related Pathways

SAPK JNK Signaling Cascades

Applications

WB IHC

Dilution

WB: 1:500~1:1000 IHC: 1:50~1:200

Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .